Bardoxolone
- Generic Name
- Bardoxolone
- Drug Type
- Small Molecule
- Chemical Formula
- C31H41NO4
- CAS Number
- 218600-44-3
- Unique Ingredient Identifier
- 7HT68L8941
- Background
Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors. It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells that are under high levels of intrinsic oxidative stress. In contrast, Bardoxolone in normal cells induces protective antioxidant/anti-inflammatory responses.
- Indication
用于治疗亚伯氏症（遗传性肾炎）导致的慢性肾病（CKD）。
A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)
- Conditions
- Chronic Kidney Diseases
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 81
- Registration Number
- NCT04702997
- Locations
- 🇺🇸
California Institute of Renal Research, La Mesa, California, United States
🇺🇸Renal Associates of Baton Rouge, Baton Rouge, Louisiana, United States
🇺🇸Columbia Nephrology Associates, PA, Columbia, South Carolina, United States
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
- Conditions
- ADPKDAutosomal Dominant Polycystic Kidney
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 667
- Registration Number
- NCT03918447
- Locations
- 🇺🇸
Florida Premier Research Institute, LLC, Winter Park, Florida, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
- Conditions
- Autosomal Dominant Polycystic KidneyIgA NephropathyCKD Associated With Type 1 DiabetesFocal Segmental Glomerulosclerosis
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 103
- Registration Number
- NCT03366337
- Locations
- 🇺🇸
Tufts Medical Center - Division of Nephrology Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Gulfcoast Endocrine and Diabetes Center, Clearwater, Florida, United States
🇺🇸Advanced Clinical Research, West Jordan, Utah, United States
Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 16
- Registration Number
- NCT03264079
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
- Conditions
- Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo capsules
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 202
- Registration Number
- NCT02657356
- Locations
- 🇺🇸
Wexner Medical Center at The Ohio State University, Columbus, Ohio, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Boston University School of Medicine, Boston, Massachusetts, United States
Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 179
- Registration Number
- NCT01689116
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis
- Conditions
- Type 2 Diabetes MellitusEnd-Stage Renal Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Registration Number
- NCT01576887
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Conditions
- Renal Insufficiency, ChronicDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 2185
- Registration Number
- NCT01351675
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Conditions
- Renal Insufficiency, ChronicDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 129
- Registration Number
- NCT01053936
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Conditions
- Chronic Kidney DiseaseType 2 DiabetesDiabetic Nephropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 227
- Registration Number
- NCT00811889
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.